Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T19:57:11.902Z.
Calculation as of: 2026-10-06T19:57:11.902Z.
Quote observation: 2026-10-06T19:55:23.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 48f0cd224d3c7dd52ecd2cde696dbbeed4cc913852df97ed5052446ca25b90ee
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Hyperfine, Inc.
Market Cap
$73.77M
EV/EBIT Ratio
N/A
| NAME | MARKET CAP | EV/EBIT RATIO |
|---|---|---|
| Hyperfine, Inc. (HYPR) | $73.77M | N/A |
| Verrica Pharmaceuticals Inc. (VRCA)vs › | $73.10M | N/A |
| Pulmonx Corporation (LUNG)vs › | $74.90M | N/A |
| MindWalk Holdings Corp. (HYFT)vs › | $72.60M | N/A |
| SkinHealth Systems Inc. (SKIN)vs › | $75.82M | N/A |
| Neonc Technologies Holdings, Inc. (NTHI)vs › | $75.98M | N/A |
| Gain Therapeutics, Inc. (GANX)vs › | $70.59M | N/A |
| Outset Medical, Inc. (OM)vs › | $76.75M | N/A |
| Sera Prognostics, Inc. (SERA)vs › | $77.72M | N/A |
| Inovio Pharmaceuticals, Inc. (INO)vs › | $77.73M | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
